Oncolytics Biotech Inc
TSX:ONC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.45
18.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Oncolytics Biotech Inc
Net Income
Oncolytics Biotech Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Oncolytics Biotech Inc
TSX:ONC
|
Net Income
-CA$30.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-7%
|
|
|
Theratechnologies Inc
TSX:TH
|
Net Income
-$9.2m
|
CAGR 3-Years
44%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-2%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Net Income
-$72.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income
$77.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Net Income
-$306.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-40%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Net Income
-CA$41.7m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-16%
|
|
Oncolytics Biotech Inc
Glance View
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
See Also
What is Oncolytics Biotech Inc's Net Income?
Net Income
-30.4m
CAD
Based on the financial report for Jun 30, 2025, Oncolytics Biotech Inc's Net Income amounts to -30.4m CAD.
What is Oncolytics Biotech Inc's Net Income growth rate?
Net Income CAGR 10Y
-7%
Over the last year, the Net Income growth was -9%. The average annual Net Income growth rates for Oncolytics Biotech Inc have been -7% over the past three years , -1% over the past five years , and -7% over the past ten years .